Rein Therapeutics Inc. (RNTX)

Market Cap	43.33M
Revenue (ttm)	n/a
Net Income (ttm)	-29.24M
Shares Out	21.67M
EPS (ttm)	-2.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,126
Open	2.040
Previous Close	1.970
Day's Range	1.980 - 2.050
52-Week Range	1.610 - 7.420
Beta	2.23
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 20, 2025

About RNTX

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes...

• Founded: 2001
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: RNTX
• Website: https://www.aileronrx.com